Targeting ALK in pediatric RMS does not induce antitumor activity in vivo

ConclusionsWhile ALK appears to be a relevant target in RMS in vitro, targeting this kinase in vivo yields no therapeutic efficacy, warranting extreme caution when considering the use of these agents in pediatric RMS patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research